top of page
Co-Promotion Agreements in MENA: How to Access an Established Sales Force Without Building One From Scratch
Co-promotion agreements give pharma companies access to established MENA sales infrastructure; however, only if structured correctly. Discover the five dimensions that determine co-promotion agreement value. | Nexus Pharmalink
3 min read
Joint Ventures in MENA Pharma: The Governance Decisions That Determine Whether Your JV Thrives or Fails
MENA pharma joint ventures fail predictably, and the failure mode is almost always built in at formation. Learn the governance decisions that determine JV success from day one. | Nexus Pharmalink
4 min read
The European Pharmaceutical Market: A Strategic Window for MENA Companies Seeking Innovation Access
Europe holds 30% of the global pharma market and is a primary source of in-licensing opportunities for MENA companies. Discover why EMA approval status changes the regulatory equation for MENA submissions. | Nexus Pharmalink
4 min read
Why North America Remains the World's Pharma Innovation Hub: And What That Means for Global Partnerships
North America holds 42% of the global pharma market and leads global R&D. Discover how MENA companies access North American innovation, and why the Santé Canada regulatory advantage changes the equation. | Nexus Pharmalink
4 min read
The Bidirectional Pharma Partnership Model: How MENA Players Access Western Innovation
MENA pharma companies are actively seeking Western innovation, in-licensing, co-development, and biotech access. Discover the bidirectional partnership model that creates value for both sides. | Nexus Pharmalink
4 min read
Why 70% of Pharma Expansions Into MENA Fail And How to Avoid It
70% of pharma expansions into MENA fail. Discover the 4 critical mistakes and the Nexus approach to securing your market entry. Expert guide by Sara Abbad.
2 min read
bottom of page